JAMA. 2025 Sep 3. doi: 10.1001/jama.2025.13559. Online ahead of print.
PMID:40900603
Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes.
Wessels AM, Scheltens P, Barkhof F, Heine RJ.
Eur J Pharmacol. 2008 May 6;585(1):88-96. doi: 10.1016/j.ejphar.2007.11.080. Epub 2008 Mar 4.
PMID:18396273
Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming.
Villalba A, Rodriguez-Fernandez S, Perna-Barrull D, Ampudia RM, Gomez-Muñoz L, Pujol-Autonell I, Aguilera E, Coma M, Cano-Sarabia M, Vázquez F, Verdaguer J, Vives-Pi M.
Front Endocrinol (Lausanne). 2020 May 13;11:258. doi: 10.3389/fendo.2020.00258. eCollection 2020.
PMID:32477262
A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
Bramlage P, Tittel SR, Müther S, Reinhart-Steininger B, Haberland H, Khodaverdi S, Zimny S, Ohlenschläger U, Lanzinger S, Haak T.
Acta Diabetol. 2022 Nov;59(11):1453-1460. doi: 10.1007/s00592-022-01939-3. Epub 2022 Aug 7.
PMID:35933650
The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes.
Levy BL, McCann TW Jr, Finan DA.
Eur Endocrinol. 2016 Mar;12(1):18-23. doi: 10.17925/EE.2016.12.01.18. Epub 2016 Mar 15.
PMID:29632582
Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM.
Zhang W, Chen J, Bi J, Ding N, Chen X, Wang Z, Jiao Y.
Front Endocrinol (Lausanne). 2023 Jan 4;13:1084441. doi: 10.3389/fendo.2022.1084441. eCollection 2022.
PMID:36686495
Sustained Impact of Intermittently Scanned Continuous Glucose Monitoring on Treatment Satisfaction and Severe Hypoglycemia in Adults with Type 1 Diabetes (FUTURE): An Analysis in People with Normal and Impaired Awareness of Hypoglycemia.
Charleer S, De Block C, Bolsens N, Van Huffel L, Nobels F, Mathieu C, Gillard P.